Trials / Completed
CompletedNCT03142724
Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects
Assessment of the Biodistribution and Safety of [18F]MNI-968 (Aka PF-06730110) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Molecular NeuroImaging · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-968 as a D1 receptor targeted radiopharmaceutical.
Detailed description
The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-968 as a D1 receptor targeted radiopharmaceutical. The specific objectives are: * To determine the radiation dosimetry of \[18F\]MNI-968 * To assess the safety and tolerability of a single dose of \[18F\]MNI-968
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]MNI-968 | Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans. |
Timeline
- Start date
- 2017-05-01
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
- First posted
- 2017-05-05
- Last updated
- 2018-03-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03142724. Inclusion in this directory is not an endorsement.